Ginkgo Bioworks Holdings (DNA) Operating Leases (2022 - 2026)

Ginkgo Bioworks Holdings' Operating Leases history runs 5 years deep, the most recent figure standing at $410.7 million for Q1 2026.

• Quarterly Operating Leases fell 5.49% year-over-year to $410.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $410.7 million (down 5.49% YoY) and the FY2025 annual result came in at $417.1 million, down 4.94% from the prior year.
• Operating Leases was $410.7 million for Q1 2026 at Ginkgo Bioworks Holdings, down from $417.1 million in the prior quarter.
• Across five years, Operating Leases topped out at $452.3 million in Q2 2024 and bottomed at $221.8 million in Q4 2023.
• A 5-year average of $395.6 million and a median of $415.2 million in 2022 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2023 — Operating Leases slumped 46.32% — and 2024, when it jumped 97.79%.
• Ginkgo Bioworks Holdings' Operating Leases stood at $413.3 million in 2022, then sank by 46.32% to $221.8 million in 2023, then surged by 97.79% to $438.8 million in 2024, then retreated by 4.94% to $417.1 million in 2025, then retreated by 1.53% to $410.7 million in 2026.
• Business Quant data shows DNA's Operating Leases at $410.7 million in Q1 2026, $417.1 million in Q4 2025, and $422.9 million in Q3 2025.